Hemopexin counteracts systolic dysfunction induced by heme-driven oxidative stress by Ingoglia, Giada et al.
Contents lists available at ScienceDirect
Free Radical Biology and Medicine
journal homepage: www.elsevier.com/locate/freeradbiomed
Hemopexin counteracts systolic dysfunction induced by heme-driven
oxidative stress
Giada Ingogliaa, Can Martin Sagb, Nikolai Rexb, Lucia De Franceschic, Francesca Vinchid,
James Ciminoa, Sara Petrilloa, Stefan Wagnerb, Klaus Kreitmeierb, Lorenzo Silengoa,
Fiorella Altrudaa, Lars S. Maierb, Emilio Hirscha, Alessandra Ghigoa, Emanuela Tolosanoa,⁎
a Dept. Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
b Dept. Internal Medicine II, University Hospital Regensburg, Regensburg, Germany
c Dept. Medicine, Università degli Studi di Verona–Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
d Heidelberg University Hospital / EMBL Heidelberg, Heidelberg, Germany
A R T I C L E I N F O
Keywords:
Heme
Hemopexin
ROS
Heart
Systolic function
A B S T R A C T
Heart failure is a leading cause of morbidity and mortality in patients affected by different disorders associated
to intravascular hemolysis. The leading factor is the presence of pathologic amount of pro-oxidant free heme in
the bloodstream, due to the exhaustion of the natural heme scavenger Hemopexin (Hx). Here, we evaluated
whether free heme directly affects cardiac function, and tested the therapeutic potential of replenishing serum
Hx for increasing serum heme buffering capacity.
The effect of heme on cardiac function was assessed in vitro, on primary cardiomyocytes and H9c2 myoblast
cell line, and in vivo, in Hx-/- mice and in genetic and acquired mouse models of intravascular hemolysis. Purified
Hx or anti-oxidants N-Acetyl-L-cysteine and α-tocopherol were used to counteract heme cardiotoxicity.
In mice, Hx loss/depletion resulted in heme accumulation and enhanced reactive oxygen species (ROS)
production in the heart, which ultimately led to severe systolic dysfunction. Similarly, high ROS reduced systolic
Ca2+ transient amplitudes and fractional shortening in primary cardiomyocytes exposed to free heme. In
keeping with these Ca2+ handling alterations, oxidation and CaMKII-dependent phosphorylation of Ryanodine
Receptor 2 were higher in Hx-/- hearts than in controls. Administration of anti-oxidants prevented systolic failure
both in vitro and in vivo. Intriguingly, Hx rescued contraction defects of heme-treated cardiomyocytes and
preserved cardiac function in hemolytic mice.
We show that heme-mediated oxidative stress perturbs cardiac Ca2+ homeostasis and promotes contractile
dysfunction. Scavenging heme, Hx counteracts cardiac heme toxicity and preserves left ventricular function. Our
data generate the rationale to consider the therapeutic use of Hx to limit the cardiotoxicity of free heme in
hemolytic disorders.
1. Introduction
Heart failure, one of the leading causes of morbidity and mortality
worldwide, is a multifactorial complex disorder that leads to a
disturbance of the normal pump activity of the heart to meet the
metabolic demands of the body [1]. Excess production of reactive
oxygen species (ROS) has been implicated in progression of chronic
heart failure as well as in other cardiovascular disorders including
ischemia-reperfusion injury and cardiovascular complications of hemo-
lytic diseases [2–7].
Free heme is a strong driver of oxidation and it has been shown to
affect the function of various cell components within the cardiovascular
system [8]. Heme promotes endothelial dysfunction by inducing the
expression of adhesion molecules and reducing nitric oxide (NO)
availability, which causes vasoconstriction [9–14]. Moreover, heme-
derived ROS induce the proliferation of smooth muscle cells, that
participate in vasculopathy associated with atherosclerosis and hyper-
tension [15]. Finally, heme causes oxidant damage to thick filament
proteins, leading to contractile dysfunction in human cardiomyocytes in
vitro [16].
Under physiologic conditions, heme levels are maintained in plasma
at very low concentration (0.2 µmol/L) [17]. However, in pathologic
conditions associated with intravascular hemolysis such as hemolytic
anemias (i.e. hemoglobinopathies or G6PD deficiency), heme levels rise
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up to 20–50 µmol/L [17]. Interestingly, β-thalassemia intermedia, a
paradigmatic disorder of chronic hemolysis with increased free heme,
has been associated with systolic and diastolic dysfunction, leading to
the development of heart failure, which is a life-threatening complica-
tion in these patients [18]. Although progresses have been made in the
knowledge of the pathogenesis of organ damage related to hemolytic
disorders, the molecular mechanisms leading to impaired heart func-
tion are still largely unknown and the potential contribution of free
heme-driven oxidative stress on left ventricular dysfunction has not
been clarified yet.
Hemopexin (Hx) is a plasma acute phase glycoprotein produced by
the liver and able to bind an equimolar amount of heme with high
affinity [19]. Upon heme binding, the Hx-heme complex is taken up by
the liver and heme catabolized by heme oxygenases [19]. In this way,
Hx works as a plasma buffering system to keep circulating heme at very
low concentration. Nevertheless, during sustained hemolysis, Hx is fully
saturated and free heme levels rise, leading to tissue oxidative damage
[9,20–22]. Recent studies have highlighted the potential therapeutic
role of exogenous Hx in mouse models of sickle cell disease. In sickle
cell disease mice, exogenous Hx markedly reduces inflammatory
vasculopathy, prevents the development of severe acute vaso occlusive
events and improves cardiac function [9,23,24]. Given these data, we
asked whether the beneficial effect of Hx on the cardiovascular system
might be due not only to preservation of vascular homeostasis but also
to specific effects on the heart.
Here, we show that heme impairs calcium homeostasis in cardio-
myocytes, and in turn impairs cardiac contractility, both in vitro and in
in vivo models of hemolytic disorders. Hx preserves systolic function by
preventing heme-driven ROS production and Ca2+ mishandling in
cardiomyocytes. We propose non-hemopexin bound heme (NHBH) as
new factor contributing to cardiotoxicity in chronic hemolytic diseases,
such as β-thalassemia, together with free pathologic iron (non-trans-
ferrin bound iron, NTBI). Our results support the use of Hx as a
therapeutic option to prevent severe heart complication related to
NHBH in chronic hemolytic diseases.
2. Methods
2.1. Mouse neonatal cardiomyocyte isolation and culture
Spontaneously beating neonatal cardiac myocytes were prepared
from hearts of 1- to 2-day-old mouse pups. Pups were anesthetized by
hypothermia, sacrificed via decapitation and hearts were removed.
Atria were cut off and ventricles were minced and pre-digested over-
night at 4 °C in calcium-free HEPES-buffered Hanks’ solution, pH 7.4,
containing 0.5 mg/mL trypsin (USB Corporation, Cleveland, Ohio). The
following day, ventricles were incubated at 37 °C for 5 min in calcium-
free HEPES buffered Hanks’ solution, pH 7.4, containing 330 U/mL
collagenase type II (Worthington Biochemical, Lakewood, NJ). The
digestion step was repeated 3–4 times. To reduce the contribution of
non-myocardial cells, cells were pre-plated for 1 h. The myocyte-
enriched cells remaining in suspension were plated on 35-mm tissue
culture dishes at a density of 1.5*105 cells per dish. Culture dishes were
pre-coated with a solution of 0.2% gelatin (Sigma-Aldrich, Saint Louis,
MO) and 15 mg/mL fibronectin for 30 min. Myocytes were cultured in a
Dulbecco's modified Eagle's medium/Medium 199 (Gibco, Carlsbad,
CA) mix containing 10% horse serum, 5% fetal bovine serum, and
5 mmol/L penicillin/streptomycin (Gibco, Carlsbad, CA).
The rat-derived myoblast cell line H9c2 (ATCC CRL-1446™) was
cultured in Dulbecco's modified Eagle's medium/Medium 199 (Gibco,
Carlsbad, CA) containing 10% fetal bovine serum, and 5 mmol/L
penicillin/streptomycin (Gibco, Carlsbad, CA).
2.2. Heme treatment
Hemin chloride was dissolved in dimethyl sulfoxide to obtain a 4-
mmol/L stock solution, diluted, and mixed 1:1 with human serum
albumin (CSL Behring, Switzerland) or Hx (CSL Behring, Switzerland).
Cardiomyocytes were treated with albumin-heme, Hx-heme or heme
5–10 μmol/L in culture medium until 8 h. After treatment, cells were
washed twice. H9c2 cells were treated with Hx-heme or heme 5–10
μmol/L in culture medium until 8 h. After treatment, cells were washed
twice.
2.3. Mice and Treatments
C57BL/6 Hx-/- mice and Hbbth3/+ mice as a model of β-thalassemia
were described previously [20,25–29]. All mice were housed in our
animal facility, with a 12-h dark/light cycle and access to standard
laboratory chow and tap water ad libitum. Sex- and age-matched
C57BL/6 wild-type mice were used as controls.
C57BL/6 wild-type mice were administered intraperitoneally (i.p.)
with 25 mg/kg phenylhydrazine (PHZ, Sigma-Aldrich, Saint Luis, USA)
twice a week for 4 weeks. PHZ-treated mice were injected i.p. with
160 mg/Kg Hx dissolved in PBS or 400 mg/kg α-tocopherol (Sigma-
Aldrich) dissolved in corn oil or with vehicle on the day of PHZ
injection. Control animals were injected with PBS or corn oil. Animals
were anesthetized by intramuscular injection of Zoletil (80 mg/kg)/
Xylazine (16 mg/kg), and serum and tissue samples were collected and
kept frozen until analysis.
All animal procedures were performed conform the guidelines from
Directive 2010/63/EU of the European Parliament on the protection of
animals used for scientific purposes. This study was approved by the
Italian regulatory authority (approval reference number 87/2015-PR).
2.4. Heme content
Heme content in cells and tissues was quantified fluorometrically by
the method of Sassa [30,31]. Briefly, tissues or cells were homogenized
in phosphate buffer saline (PBS) and protein content was determined by
using the Bio-Rad protein assay system (Bio-Rad, Munchen, Germany).
Ten ug of protein samples were incubated with 0.5 mL of 2 M Oxalic
Acid (Sigma-Aldrich) at 95 °C for 30 min. Samples were subsequently
centrifuged at 14,000 rpm for 5 min. Fluorescence emission in the
supernatant was determined spectrofluorimetrically (Glomax, Promega
Italia). Excitation and emission wavelengths were set at 405 and
662 nm, respectively. The background was evaluated by measuring
fluorescence in non-boiled samples.
2.5. Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA, from cells or tissues, was extracted using Pure Link RNA
Mini Kit (Ambion, Life Technologies Italia, Milano, Italy). One µg total
RNA was reverse transcribed using M-MLV reverse transcriptase and
random primers (Life Technologies Italia). qRT-PCR was performed on
a 7300 Real Time PCR System (Applied Biosystems, Life Technologies
Italia). Primers and probes were designed using the ProbeFinder
software (http://www.roche-applied-science.com). All results were
normalized to 18S mRNA.
2.6. Protein extraction and western blotting
Tissue and cell proteins were extracted as reported [20] and
concentration was determined using the Bio-Rad protein assay system
(Bio-Rad, Munich, Germany). Fifty µg total protein or 0.25 µL mouse
serum in 8 µL of Laemly Buffer were separated on 4%, 8% or 12%
sodium dodecyl sulfate polyacrylamide gel electrophoresis and ana-
lyzed by Western blotting using antibodies against HO-1 (dilution
1:300, Enzo Life Sciences), TfR1 (dilution 1:1000, Invitrogen), ox-
CAMKII (dilution 1:1000, Gene Tex), tot-CAMKII (dilution 1:1000, Cell
Signaling), RYR2 pSer 2814 (dilution 1:2500, Badrilla), total RYR2
(dilution 1:5000, Thermo Scientific), PLB pThr17 (dilution 1:1000,
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Badrilla), total PLB (1:1000, Merck Millipore), Hx (1:1000) [20], N-Tyr
(1:1000, Merck Millipore).
2.7. RyR2 oxidation
To detect RyR2 protein oxidation, hearts were homogenized in
120 mmol/L NaCl, 50 mmol/L Tris–HCl (pH 8.0) and 1% Triton X-100,
supplemented with protease and phosphatase inhibitors. After 30 min
incubation on ice, lysates were centrifuged at 3000 rpm for 5 min at
4 °C and immunoprecipitated. Four mg of pre-cleared extracts were
incubated with 20 µL of protein G-Sepharose (Amersham Biosciences,
Buckinghamshire, UK) and 4 µg of anti-RYR2 antibody (Thermo
Scientific), for 2 h at 4 °C. Immunoprecipitates were washed, treated
with 2, 4-dinitrophenyl (DNP) hydrazine, separated on 4% SDS-PAGE
and transferred onto PVDF membranes. The RYR2 DNP-derivatized
carbonyls were detected using an OxyBlot Protein Oxidation Detection
Kit (Merck Millipore); total RYR2 was detected with an anti-RyR2
antibody (Thermo Scientific).
2.8. ROS production assay
Accumulation of ROS in heart homogenates or cells was assessed by
using the oxidant-sensitive fluorescent dye 29,79-dichlorodihydrofluor-
oscein diacetate (H2DCFDA; Molecular Probes, Inc., Eugene, OR) as
previously described [32]. Heart homogenates or cell extracts were
incubated with 5 µM H2DCFDA in phosphate buffered saline (PBS) or in
serum-free medium, respectively, for 30 min at 37 °C under 5% CO2
atmosphere. Fluorescence was recorded at excitation and emission
wavelengths of 485 nm and 530 nm respectively, by a fluorimeter plate
reader (Promega). The background fluorescence caused by PBS or
medium and DCF was subtracted from the total fluorescence in each
well generated by cells in presence of DCF. Fluorescence intensity was
expressed as arbitrary fluorescence units/mg protein.
Following incubation for 6 h, adult rat cardiomyocytes media was
discarded and replaced with the ROS sensitive fluorescent dye CM-
H2DCFDA (at 10 µM, Invitrogen, USA). For ROS measurements, cells
were excited at 485±15 nm on a Nikon Eclipse TE2000-U inverted
microscope which was provided with a fluorescence detection system
(ION OPTIX, Milton, MA, USA). Emitted fluorescence was collected at
535±20 nm for only 10 s every min to prevent photooxidation of the
dye [33].
2.9. Lipid peroxidation assay
Lipid peroxidation from tissue extracts was measured with the
colorimetric assay kit Bioxytech LPO-586 from Oxis International
(Portland, OR) according to the manufacturer's instructions.
2.10. Immunohistochemistry and histology
Hearts were fixed in 10% formalin overnight at room temperature
and embedded in paraffin. Microtome sections, 5-μm thick, were
incubated overnight with anti-HO-1 (Enzo Life Sciences) or anti-
CD18 (Biolegend) antibody, both diluted 1:100, followed by biotin-
conjugated secondary antibody. For collagen quantification, sections
were stained with Picrosirius Red [34]. The sections were visualized on
an Olympus BH-2 microscope, coupled to an Olympus camera. Collagen
content was calculated as a percentage of the red-stained area per
section by using Image J program.
2.11. Echocardiography
Transthoracic echocardiography was performed with a small animal
high-resolution imaging system (VeVo2100, VisualSonics, Inc, Toronto,
Canad) equipped with a 22–55 MHz trasducer (MicroScan Transducers,
MS500D)12. The mice, anesthetized by isoflurane (2%) inhalation and
maintained by mask ventilation (isoflurane 1%), were placed in a
shallow left lateral decubitus position, with strict thermoregulation
(37±1 °C) to optimize physiological conditions and reduce hemody-
namic variability. Fur was removed from the chest by application of a
cosmetic cream to gain a clear image. Echocardiographic parameters
were measured at the level of the papillary muscles in the parasternal
short-axis view (M mode). LV fractional shortening was calculated as
follows: FS =((LVEDD - LVESD)/ LVEDD)×100, where LVFS indicates
LV fractional shortening; LVEDD, LV end-diastolic diameter; and
LVESD, LV end-systolic diameter. LV ejection fraction was calculated
automatically by the echocardiography system. All measurements were
averaged on 5 consecutive cardiac cycles per experiment and cardiac
function was assessed when heart rate was 450–500 bpm.
2.12. Adult rat cardiomyocyte isolation and culture
A modified protocol for rat myocytes isolation [35] was used. Adult
8–10 week old Sprague dawley rats (Janvier labs) were anaesthetized
with isoflurane (2%) (Abbott, Wiesbaden, Germany). Afterwards, hearts
were carefully excised and mounted on a Langendorff-perfusion
apparatus, and subsequently perfused for 3 min with nominal Ca free
solution. Next, the heart was perfused for ≈15 min with an "enzyme
solution" containing (in mmol/L) NaCl 113, KCl 4.7, KH2PO4 0.6,
Na2HPO4×2H2O 0.6, MgSO4×7H2O 1.2, NaHCO3 12, KHCO3 10,
HEPES 10, Taurine 30, Glucose 5.5, BDM 10, and CaCl2 0,0125, (all
Roth, Karlsruhe, Germany), Liberase TM (1,5 mg, Roche, Mannheim,
Germany), Trypsin 2,5%, (180 µL, Gibco, Paisley, UK). After digesting
the extracellular matrix up to the point of visible tissue solution, the
heart was transferred into a glass basin that was filled with an enzyme-
free "stop solution" that contained the same ingredients as the enzyme
solution without the enzyme, but with BCS 10%, The atria were
afterwards carefully separated from the ventricles and discarded.
Subsequently, the ventricles were cut with preparatory scissors into
small pieces of tissue. The cell suspension was filtered through a nylon
gaze. After sedimentation of the tissue, stop solution was removed and
replaced with a second enzyme free solution containing 5% BCS. Using
this solution, Ca reintroduction was performed by stepwise increasing
[Ca] from 0.1 to 1.2 mmol/L. Ca loaded cells were afterwards resus-
pended in Ca containing "cell culture media" consisting of M199
(Sigma-Aldrich) plus 1% Penicillin/Streptomycin and 1% Insulin-
Transferrin-Streptomycin and transferred into Laminin-coated culture
dishes. Hemin (H651-9, Frontier Scientific) as diluted in PBS to achieve
a concentration of 50 µM was added at 5 µM vs. PBS control (vehicle) to
the culture dish. In an independent set of experiments, an equal volume
of 50 µM heme solution was mixed with a 50 µM Hx solution and
incubated for 1 h at 37° in the dark, in order to form a Hx-heme
complex. Hx-heme solution was similarly added to an according culture
dish at 5 µM. In some experiments, N-Acetyl-L-cysteine (NAC, A7250
from Sigma-Aldrich) was added at 10 mM to heme-treated cells. Cell
were afterwards cultured for 6 h at 37 °C in darkness.
2.13. Ca2+ measurements
Following incubation for 6 h, cell culture media was discarded and
replaced with the Ca2+ sensitive fluorescent dye Fura-2 AM (at 10 µM,
Invitrogen, USA). For Ca2+ measurements, cells were excited at 340 nm
and 380 nm and emitted fluorescence was collected at 510 nm. Ca2+
transient amplitude was assessed as the 340/380 nm fluorescence ratio
(F340nm/F380nm in ratio units, r.u.) after subtraction of background
fluorescence at each excitation wavelength [33]. Myocytes were field-
stimulated at 20±4 V at 1 Hz for ~5 min until steady-state conditions
were achieved. Myocytes were superfused with an experimental
"normal Tyrode's (NT)" solution containing (in mmol/L) NaCl 140,
KCl 4, glucose 10, HEPES 5, MgCl2 1, CaCl2 1.2, which has supple-
mented with PBS (vehicle) or hemin (at 5 µM) at 22 °C (pH 7.4). Red
light transillumination was used to visualize myocytes sarcomeres.
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2.14. Statistical analysis
Results were expressed as mean± SEM. Prism software (GraphPad
software Inc, La Jolla, CA) was used for statistical analysis.
Comparisons between 2 groups were performed with 2-sided Welch t-
tests and among>2 groups with 1- or 2-way ANOVA followed by the
Bonferroni post-test. A value of P<0.05 was considered significant.
3. Results
3.1. Hemopexin protects neonatal cardiomyocytes from heme accumulation
and ROS production
Recently, we showed that, by scavenging heme, Hx prevents heme
accumulation in endothelial and immune cells, thus limiting heme
toxicity [9,36]. To evaluate whether cardiomyocytes (CMs) may also be
affected by pathologic free heme, we treated mouse neonatal CMs with
10 µM heme, in presence of either Hx or Albumin (a low affinity heme-
binding protein [17]).
Fig. 1. Hemopexin protects neonatal cardiomyocytes from heme accumulation and ROS production. Data on neonatal cardiomyocytes isolated from the hearts of postnatal day 0–1 wild-
type (Wt) pups, untreated (NT) or treated with 10 µM Hx-heme complex, 10 µM Albumin (Alb)-heme complex or 10 µM heme for 8 h, are shown. (A) Cardiomyocyte heme content. (B)
qRT-PCR analysis of Ho-1 mRNA levels. (C) Western blot analysis of HO-1. (D) Cardiomyocyte ROS content and (E) immunofluorescence analysis of super-oxide radical formation (super-
oxide radical was stained with Mito-sox fluorescent probe. Nuclei were stained with DAPI). (F) qRT-PCR analysis of Gsr mRNA levels. Results shown are representative of three
independent experiments. One-way analysis of variance with Bonferroni post-test analysis was performed. *P< 0.05; **P< 0.01; ***P< 0.001. Values represent mean± SEM. AU,
arbitrary units; RQ, relative quantity; FIU, fluorescence intensity unit.
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Hx-heme-treated CMs were protected from heme accumulation,
compared to cells treated with albumin-heme or heme alone (Fig. 1A),
indicating that Hx prevents heme entry in cardiac cells. Consistently,
the mRNA and protein levels of the heme-degrading enzyme Heme
Oxygenase (HO)−1 were significantly more elevated in cells treated
with either albumin-heme or heme alone compared to cells treated with
Hx-heme (Fig. 1B, C). These results were confirmed in the H9c2
myoblast cell line treated with Hx-heme or heme alone (see Fig. 2 in
[37]). Moreover, in CMs the heme-mediated induction of the iron
exporter Ferroportin (Fpn) was abrogated by Hx treatment while the
down-regulation of the iron importer Transferrin receptor 1 (TfR1) was
significantly reduced by Hx (see Fig. 3 in [37]) further indicating that
Hx limits heme-iron accumulation within the cell. Consistently, Hx
treatment blunted heme-mediated induction of the heme exporter
Feline Leukemia Virus subgroup C Receptor 1(Flvcr1) [31,38,39] in
H9c2 cells (see Fig. 3 in [37]). Taken together, these data demonstrate
that Hx prevents/limits heme accumulation in CMs.
Being heme a well-known pro-oxidant agent [17], we then evalu-
ated ROS levels in CMs exposed to heme alone or bound to either Hx or
albumin. In the presence of Hx-heme complexes, CMs were protected
from ROS formation, if compared to CMs treated with either albumin-
heme complexes or heme alone (Fig. 1D). Staining of CMs with a
fluorescent probe for specific detection of mitochondrial superoxide
(Mito-sox) confirmed lower oxidative stress in cells exposed to Hx-heme
Fig. 2. Hemopexin prevents heme-driven cardiac oxidative stress. Data on the heart of Wt and Hx-/- mice are shown. (A) Heme content (n=5). (B) qRT-PCR, representative western blot
and immunohistochemistry analysis for HO-1. (C) ROS content (n=13) and (D) malondialdehyde (MDA; n =8) content. (E) qRT-PCR analysis of Gsr mRNA levels. In Western blot shown
in B, each lane represents an individual animal; Bip was used as loading control. Unpaired t-test analysis with Welch's correction was performed. Values represent mean±SEM.
*P< 0.05.
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than in those exposed to albumin-heme or heme alone (Fig. 1E).
Consistently, the mRNA levels of Glutathione reductase (Gsr), γ-
Glutamylcysteine synthetase (γ-Gcs) and thioredoxin reductase
(Thiored red), anti-oxidant systems important in resistance of cardiac
cell to oxidative damage [40,41], were increased to a higher extent in
CMs treated with either albumin-heme or heme alone, compared to
cells treated with Hx-heme (Fig. 1F and see Fig. 3 in [37]). The data
were reproduced in H9c2 cells in which we were also able to
demonstrate that Hx limits protein nitrosylation, another hallmark of
cellular oxidative damage (see Fig. 2 in [37]).
Taken together, these data demonstrate that Hx protects cardiac
cells against heme accumulation and related oxidative stress.
Fig. 3. Hemopexin prevents heme overload-induced heart dysfunction. Data on the heart of Wt and Hx-/- mice (A-C), Wt and β-thalassemic (β-Thal) mice (D-F) and PHZ-treated Wt mice
(G-I) are shown. (A) Representative M-mode echocardiogram of a Wt and an Hx-/- mouse. (B) Fractional shortening and (C) ejection fraction at 3 (Wt n=10; Hx-/- n=20) and 6 (Wt n=5;
Hx-/- n=3) months of age. (D) Representative M-mode echocardiogram of a Wt and a β-thalassemic mouse. (E) Fractional shortening and (F) ejection fraction (Wt n=3; β-Thal n=6). (G)
Representative M-mode echocardiogram of a Wt mouse at time 0 and after 4 weeks of PHZ treatment. (H) Fractional shortening and (I) ejection fraction (n=10). Two-ways analysis of
variance with Bonferroni post-test analysis (B-C) and unpaired t-test analysis with Welch's correction (E-F, H-I) were performed. *P< 0.05; **P<0.01; ***P<0.001. Values represent
mean± SEM.
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3.2. Hemopexin prevents heme-driven oxidative stress in the heart
To assess whether the protective role of Hx observed in vitro is
relevant also in vivo, we took advantage of Hx knockout (Hx-/-) mice
[25]. 3 month-old Hx-/- mice showed a higher content of heme in the
heart than age-matched wild-type animals (Fig. 2A). Consistently, HO-1
mRNA and protein levels were higher in hearts from Hx-/- mice than in
controls (Fig. 2B). Immunohistochemistry for HO-1 on heart sections
indicated higher HO-1 expression in cardiomyocytes from Hx-/- mice
than in wild-type animals (Fig. 2B). Moreover, the mRNA levels of Fpn
and Flvcr1a were increased in Hx-/- mice, whereas those of the iron
importers Divalent Metal Transporter 1 (Dmt1) and Tfr1 were de-
creased (see Fig. 4 in [37]). TFR1 down-modulation was also confirmed
at the protein level (see Fig. 4 in [37]).
To evaluate the oxidative stress in the heart, we analyzed ROS levels
and lipid peroxidation in Hx-/- and wild-type mice. Both ROS and lipid
peroxidation were increased in the heart of Hx-/- mice compared to that
of wild-type animals (Fig. 2C, D). Consistently, the oxidative stress
responsive gene Gsr was up-regulated in the heart of Hx-/- mice
compared to wild-type animals (Fig. 2E).
Altogether, these data demonstrate a critical role for Hx in
preventing heme-driven oxidative stress in the myocardium.
3.3. Hemopexin prevents heme overload-induced heart dysfunction
To evaluate whether heme-driven oxidative stress impairs heart
function, we performed echocardiography on Hx-/- and control mice.
Cardiac contractility was severely impaired in 3 month-old Hx-/- mice
compared to wild-type controls, as evidenced by significantly lower
fractional shortening (FS) and ejection fraction (EF) (Fig. 3A-C).
Notably, in Hx-/- mice, systolic dysfunction worsened at 6 months of
age (Fig. 3A-C), indicating an age-dependent progression of ventricular
dysfunction, which was not associated to left side chamber dilation or
left ventricular hypertrophy (Table 1). No evidences of collagen
deposition or leukocyte infiltration in Hx-/- heart were observed,
despite a slight transcriptional up-regulation of pro-inflammatory
Interleukin 6 (IL-6) and tumor necrosis factor-α (TNF-α) (see Fig. 5 in
[37]). To dissect the cardiotoxic effect of free heme, we evaluated
systolic function in Hbbth3/+ mice used as model of non-transfusion
dependent β-thalassemia intermedia [29,42]. Interestingly, a similar
systolic dysfunction was observed in β-thalassemic mice (Fig. 3D-F and
Table 2) that are hallmarked by a high rate of intravascular hemolysis
as evidenced by Hx depletion in serum, HO-1 induction at mRNA and
protein level in the heart and altered cardiac expression of iron and
anti-oxidant genes (see Fig. 6 in [37]). These data further strength the
link between plasma Hx depletion/heme overload and defective heart
function.
Fig. 4. Hemopexin prevents heme-induced Ca2+ mishandling. Data on isolated adult rat CMs exposed to heme (5 µM), Hx-heme (5 µM), NAC-heme (10 mM) or vehicle (Nt) are shown.
Representative calcium transients (A), and representative single cell contractility (B) of untreated, heme-treated, Hx-heme-treated and NAC-heme-treated CMs. Bar graphs represent (C)
systolic calcium transient amplitude, as the difference of peak amplitude of the fluorescence (ΔF340/380= F340/380 peak− F340/380 basal), (D) relaxation kinetics as Ca2+ decay and
(E) contractility of untreated (n =37) heme-treated (n =103), heme-Hx-treated (n =91) and heme-NAC-treated (n=22) CMs. t-test analysis with Welch's correction was performed.
*P< 0.05. Values represent mean± SEM.
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Table 1
Echocardiographic parameters of Wt and Hx-/- mice.
ECHOCARDIOGRAPHY Wt Hx -/- t-test
Left ventricle internal dimension
(diastole) (mm)
3,35±0,25 3,65± 0,27 NS
Left ventricle internal dimension
(systole) (mm)
1,84±0,07 2,42± 0,27 P≤0.01
Intraventricular septum (diastole)
(mm)
0,79±0,09 0,79± 0,04 NS
Intraventricular septum (systole)
(mm)
1,25±0,13 1,24± 0,06 NS
Left posterior wall (diastole) (mm) 0,74±0,08 0,82± 0,06 NS
Left posterior wall (systole) (mm) 1,13±0,11 1,21± 0,06 NS
Hypertrophic index 0,83±0,13 0,97± 0,07 NS
Left ventricle mass (mg) 70,26± 11,52 79,69± 13,56 NS
Fig. 5. Hemopexin prevents oxidative alteration of Ca2+ handling proteins. Data on the heart of Wt and Hx-/- mice are shown. (A) Immunoprecipitation of oxidized RyR2. RyR2 was
immunoprecipitated with a specific antibody and blotted with either oxyblot or the specific antibody. (B) Western blot analysis of α and β oxidized CaMKII and total CaMKII. α and β
oxidized CaMKII were normalized on total CaMKII. Western blot analysis of (C) phosphorylated RyR 2 at serine 2814 (RYR2 pSer2814) normalized on total RYR2, and (D) phosphorylated
PLB at threonine 17 (PLB pThr17) normalized on total PLB. A representative blot of at least 3 independent experiments is shown. For densitometry analyses on the right, n=5 for each
genotype. In B-D, Total CaMKII, RYR2 and PLB are normalized on vinculin, used as a loading control. Unpaired t-test analysis with Welch's correction was performed. *P< 0.05;
**P< 0.01. Values represent mean±SEM.
Table 2
Echocardiographic parameters of Wt and β-thalassemic (β-Thal) mice.
ECHOCARDIOGRAPHY Wt β -Thal t-test
Left ventricle internal dimension
(diastole) (mm)
4,09±0,32 4,60± 0,35 NS
Left ventricle internal dimension
(systole) (mm)
2,59±0,22 3,28± 0,32 P<0.05
Intraventricular septum (diastole)
(mm)
0,66±0,12 0,77± 0,08 NS
Intraventricular septum (systole)
(mm)
1,22±0,14 1,24± 0,12 NS
Left posterior wall (diastole) (mm) 0,77±0,10 0,80± 0,08 NS
Left posterior wall (systole) (mm) 1,21±0,21 1,15± 0,16 NS
Hypertrophic index 0,98±0,16 1,41± 0,08 P<0.05
Left ventricle mass (mg) 86,29± 27,07 116,65± 23 NS
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Fig. 6. Hemopexin protective effects are mediated by its anti-oxidant properties. Data on the heart of PHZ-treated Wt mice administered or not with α-tocopherol or Hx are shown. (A)
ROS content and (B) qRT-PCR analysis of Thiored Red and Gsr mRNA levels in untreated (n=12), PHZ- (n=8) and PHZ-α-tocopherol-treated Wt mice (n=7). (C) qRT-PCR analysis of Ho-
1 and (D) Thiored Red and Gsr mRNA levels in untreated (n=12), PHZ- (n=6) and PHZ-Hx-treated Wt mice (n=5). (E) Representative M-mode echocardiogram of Wt mice at time 0 and
4 weeks after PHZ or PHZ and α-tocopherol treatment. (F) Fractional shortening and (G) ejection fraction of PHZ- (n=6) mice and PHZ-α-tocopherol-treated mice (n=7) 4 weeks after
the treatment. (H) Representative M-mode echocardiogram of Wt mice at time 0 and 4 weeks after PHZ or PHZ and Hx treatment. (I) Fractional shortening and (J) ejection fraction of
PHZ- (n=12) and PHZ-Hx-treated mice (n=6) 4 weeks after the treatment. One-way analysis of variance with Bonferroni post-test analysis (A-D) and two-ways analysis of variance with
Bonferroni post-test analysis (F-G, I-L) were performed. *P< 0.05; **P< 0.01; ***P< 0.001. Values represent mean±SEM.
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Finally, to demonstrate that exogenous heme is the main responsible
for systolic dysfunction when Hx is lost, we performed echocardiogra-
phy in wild-type mice treated with the hemolytic agent phenylhydra-
zine (PHZ). PHZ treatment resulted in an almost complete depletion of
serum Hx and in an up-regulation of heme- and oxidative stress-
responsive genes in the heart (see Fig. 7 in [37]). Consistently with
our observations in both Hx-/- mice and β-thalassemic mice, a sig-
nificant reduction of FS and EF was observed in PHZ-treated wild-type
animals (Fig. 3G-I).
These data collectively indicate that heart free heme accumulating
when Hx is lost is responsible for systolic dysfunction.
3.4. Hemopexin prevents heme overload-induced Ca2+ mishandling
In a next step, we aimed to investigate the cellular mechanisms
underlying reduced systolic function associated with heme overload
Fig. 7. A model for Hx function in the heart. In hemolytic conditions, non-hemopexin bound heme (NHBH) level rises up and (A) heme accumulates within cardiomyocytes perturbing
heme/iron homeostasis and leading to ROS formation (cell on the left). ROS modify Ca2+-handling proteins leading to altered Ca2+ fluxes within the cell (on the right). This ultimately
results in impaired contraction. The treatment with antioxidants (NAC or α-tocopherol) rescues ROS-induced cardiomyocyte damage. (B) Hx, by scavenging NHBH, preserves both heme/
iron and Ca2+ homeostasis. Our data suggest that in hemolytic disorders, plasma heme scavenging capacity might be increased by Hx administration thus limiting heme toxicity on the
heart.
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and oxidative stress, observed in Hx-/- mice. Since oxidative stress is
known to directly impair Ca2+ handling [43], we investigated ROS
production and Ca2+ handling in isolated adult rat CMs exposed to
5 µM heme for 6 h. In agreement with data on pro-oxidant effects of
heme in neonatal mouse CMs (Fig. 1D-F), oxidative stress was
significantly increased in adult rat CMs exposed to free heme (see
Fig. 1 in [37]). Accordingly, heme-treated adult CMs had significantly
reduced systolic Ca2+ transient amplitudes (by 37%, Fig. 4A-C) in the
face of slowed relaxation kinetics, indicating reduced SR Ca2+ re-
uptake upon heme exposure (Fig. 4D). In line with this, fractional
shortening of isolated heme-treated CMs was significantly reduced as
compared to vehicle-treated CMs (Fig. 4E). Vice versa, ROS-scavenging
by the use of NAC (10 mM) attenuated heme-dependent Ca2+-mis-
handling and largely preserved single cell contractility (Fig. 4A-E). As
well as NAC, Hx co-treatment significantly improved systolic Ca2+
transients and accelerated Ca2+ transient decay kinetics, which re-
sulted in a significant improvement of cardiomyocyte contractility
(Fig. 4A-E).
In keeping with these Ca2+ handling alterations, Hx-/- hearts
displayed a higher amount of oxidized ryanodine receptor 2 (RYR2)
than wild-type controls (Fig. 5A), which may have further contributed
to disturbed SR Ca handling on top of decreased SR Ca2+ reuptake,
which was evidenced by slower kinetics of diastolic Ca2+ decay.
Furthermore, Hx-/- hearts showed a more pronounced oxidation of
the intracellular stress kinase Ca2+/Calmodulin-dependent protein
kinase II (CaMKII) (Fig. 5B). Consistently, CaMKII-dependent phosphor-
ylation of RyR2 (Ser-2814) and Phospholamban (PLB) (Thr-17) were
significantly higher in Hx-/- hearts than in wild-type controls (Fig. 5C,
D).
Altogether, these data unravel a key role for Hx in preventing
systolic dysfunction related to heme-driven oxidative stress and Ca2+
mishandling.
3.5. Hemopexin cardioprotective effect is mediated by its anti-oxidant
properties
Our data demonstrate that free heme accumulating in the heart
when Hx is lost promotes systolic dysfunction. Moreover, our in vitro
results suggest that Hx is protective because it limits heme-driven
oxidative stress, as well as the anti-oxidant NAC. To confirm these data
in vivo, we performed rescue experiments in hemolytic mice treated
with either Hx or the anti-oxidant agent α-tocopherol.
Wild-type mice were treated with PHZ and Hx, α-tocopherol or
vehicle for 4 weeks. As expected, α-tocopherol treatment prevented
ROS accumulation and the induction of anti-oxidant genes in the heart
(Fig. 6A, B and see Fig. 8 in [37]). Hx treatment similarly prevented
heme accumulation within the heart as demonstrated by the blunted
induction of HO-1 in Hx-treated hemolytic mice, and normalized anti-
oxidant gene expression profile (Fig. 6C, D). Importantly, when mice
were treated with PHZ together with either Hx or α-tocopherol, systolic
function was preserved (Fig. 6E-J).
We conclude that Hx is cardioprotective because it limits heme-
driven oxidative damage.
4. Discussion
Here, we show that Hx preserves systolic function by preventing
heme-driven ROS accumulation in cardiomyocytes and the ensuing
perturbation of Ca2+ handling (Fig. 7). This has potentially important
implications for patients suffering from pathologic conditions asso-
ciated with free heme and heme overload, such as hemolytic anemias
and hemoglobinopathies.
Data obtained in Hx-/- mice indicate that Hx has a key homeostatic
role in preserving ventricular function under steady-state, when the
physiological rate of hemolysis is very low and is well-controlled by
physiologic systems such as Hx or haptoglobin [44]. Although a role for
pathologic free iron (non-transferrin bound iron, NTBI) has been
suggested in non-transfusion-dependent and transfusion-dependent
hemolytic anemias [45,46], our data highlight a novel concept that
heart might be susceptible to acute exposure to free heme (non-
hemopexin bound heme, NHBH), and that Hx critically maintains
cardiomyocyte function by scavenging free heme and avoiding cell
heme overload (Fig. 7). The specific uptake of Hx-heme complexes by
the liver ultimately allows safe terminal heme detoxification [19].
Notably, the cardioprotective role of Hx can be even more critical in
circumstances of chronic hemolysis as occurs in hemolytic disorders
when huge amount of hemoglobin is released into the bloodstream. It
has been shown that free hemoglobin affects heart function in rabbits
and exacerbates cardiotoxicity of LPS in experimental models of sepsis
[47–49]. The heme moiety of hemoglobin, which is released following
hemoglobin oxidation in the pro-oxidant plasma milieu, is thought to
mediate hemoglobin toxicity [50]. Our finding that Hx prevents systolic
dysfunction in an experimental model of intravascular hemolysis, such
as in PHZ-treated mice, supports this view and conclusively proves a
causative role for NHBH in left ventricular dysfunction associated to
hemolytic disorders. Furthermore, Hx could be important in case of
cardiac valve surgery, where mechanical forces and shear stress are
significantly increased [51,52]. Consistently, hemolysis associated to
high shear stress has been reported after mitral valve repair [51,52] and
could contribute to heart failure in these patients.
Finally, we can speculate that Hx is beneficial during cardiac
infarction, when myoglobin is released from injured cardiomyocytes.
Once liberated from muscle cells, myoglobin rapidly auto-oxidizes,
which in turn promotes the spontaneous loss of hemin [53–56] that
might contribute to the establishment of oxidative stress and systolic
dysfunction.
Heme is a strong driver of oxidation since iron can participate in the
Fenton reaction for producing the hydroxyl radical. As a hydrophobic
molecule, heme intercalates into lipid membranes promoting lipid
peroxidation, both at the plasma membrane and in subcellular com-
partments [8,13,17]. Consistently, we measured increased lipid perox-
idation in both cells and tissues exposed to free heme, which can be
rescued by α-tocopherol, an agent able to react with lipid radicals and
interrupt the oxidation reaction. Mechanistically, heme-derived ROS
may directly modify Ca2+ handling proteins (such as the RyR2 or
SERCA2a) [35,57], and may also activate intracellular stress kinases,
such as CaMKII [58], which in turn phosphorylate the same Ca2+
effectors and ultimately exacerbate Ca2+ mishandling. In agreement,
heme has been previously reported to promote oxidation of myofila-
ment proteins, including filamin C, myosin heavy chain, cardiac myosin
binding protein C, and α-actinin in human cardiomyocytes [16].
Our data further extend this view and indicate that free heme
triggers oxidation of major regulators of Ca2+ trafficking, such as RyR2,
in vivo. Furthermore, oxidatively activated CaMKII was increased in
Hx-/- hearts and was paralleled by CaMKII-specific hyperphophoryla-
tion of RyR2 and PLB. Altogether, these modifications of Ca2+ effectors
were associated with impaired intracellular Ca2+ handling, resulting in
decreased single cell contractility, which points to disrupted Ca2+
handling in cardiac myocytes as a major mechanism underlying the
impaired cardiac function of Hx-/- mice. In particular, the finding that
Ca2+ transient decay kinetics, as an approximation of SR Ca2+
reuptake, were significantly slower in the absence of Hx, suggests that
the direct effects of ROS on SERCA2a/PLB function overcome CaMKII-
dependent effects on PLB, which would instead lead to accelerated SR
Ca2+ reuptake. On the other hand, CaMKII-dependent regulation of
RyR2 and heme-induced oxidation of RyR2 both contribute to diastolic
SR Ca2+ leakage and SR Ca2+ depletion and tend to decrease SR Ca2+
stores. Intriguingly, treatment with Hx or NAC preserves intracellular
Ca2+ handling and single cell contractility and thus further supports a
model where direct heme/ROS-mediated effects on Ca2+ handling
proteins is the main cause of reduced cardiac function when Hx is
depleted.
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Intriguingly, intracellular hemin can trigger oxidative modification
of the mitochondrial outer membrane voltage-dependent anion channel
(VDAC) [59], thus impairing mitochondrial Ca2+ influx [60]. This has
been uncovered in endothelial cells and a similar mechanism is likely to
occur in cardiomyocytes. Given the close juxtaposition of SR RyR Ca2+
channels and mitochondrial calcium transporters [61], alterations in
sarcoplasmic Ca2+ homeostasis are expected to further amplify mito-
chondrial ROS generation [62], exacerbating the pro-oxidant cardio-
myocyte status.
It is of note that SR Ca2+ leakage resulting from either hyper-
phosphorylation or oxidation of RyR2 is a major determinant of
ventricular arrhythmias [43,63] and these electrical abnormalities also
represent one of the most severe complications in patients carrying
mechanical circulatory support devices, a condition in which the heart
is subjected to high shear stress [64]. Our data showing RyR2
alterations and Ca2+ mishandling in heme-exposed cardiomyocytes
thus suggest that heme might display a pro-arrhythmogenic effect. This
is of particular interest in the context of non-transfusion dependent β-
thalassemic syndromes, largely complicated by heart failure and severe
arrhythmias [65–67].
Altogether, our findings have important implications for the treat-
ment of pathologic conditions associated with heme overload. In fact,
heart disease is the primary determinant of prognosis and survival in
hemolytic disorders [18,68]. In β-thalassemia patients, cardiac compli-
cations represent the primary cause of mortality and one of the major
causes of morbidity [18,68]. In these patients, heart failure is the result
of impaired left systolic function and ventricular dilatation, resulting
from multiple factors [18]. Among them, NTBI has been recently
recognized as initiating factor of cardiomyopathy in β-thalassemic
patients [45,46,69]. NTBI results from multiple blood transfusions
and increased iron absorption associated with ineffective erythropoi-
esis, and it is cleared preferentially by the liver and the myocardium, at
a rate exceeding 200 times that of transferrin-bound iron [45,70]. In the
heart, NTBI catalyzes the formation of free radicals, resulting in
oxidative stress that eventually contributes to organ dysfunction. Here,
we propose NHBH as new and additional factor participating to left
ventricular dysfunction in β-thalassemia. Indeed, our data in β-thalas-
semic mice highlight an association between Hx depletion/heme over-
load in the heart and systolic dysfunction, suggesting that the seques-
tration of NHBH by exogenous Hx might provide further benefits in
limiting free-heme related organ damage. We can speculate that a
combined therapy with iron and heme chelators would be beneficial in
counteracting cardiac damage induced by NTBI and NHBH. Collec-
tively, our data support the use of Hx as a therapeutic option to
prevent/limit heme-driven cytotoxicity in heme-overload conditions.
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